Rate of All-cause Hospitalization at Year 2 Between Treatment Groups Following Diagnosis of Nontuberculous Mycobacterial Lung Disease in the USA. (4th October 2017)

• Record Type: Journal Article
• Authors: Marras, Theodore; Mirsaeidi, Mehdi; Chou, Engels; Eagle, Gina; Zhang, Raymond; Wang, Ping; Zhang, Quanwu
• Is Part Of: Open forum infectious diseases. Volume 4(2017)Supplement 1
• Page Start: S674
• Page End: S674
• Publication Date: 2017-10-04
• Subjects: Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofx163.1801
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: The study compared rates of hospitalization between treatment groups in patients with nontuberculous mycobacterial lung disease (NTMLD) in a US national managed care claims database. Methods: Patient ( N = 1039) pharmacy claims at year 1 following NTMLD diagnosis were classified into 3 treatment groups including triple combo (macrolide + ethambutol + rifamycin ± other drugs) (G1), other antibiotics used by physicians for NTMLD (G2), and no treatment (G3). Hospitalization rates at year 2 were compared between treatment groups using mixed effects logistic regression to adjust for patient characteristics and comorbidities measured by Charlson Comorbidity Index (CCI) during the 12 months prior to NTMLD diagnosis (baseline). Results: Mean age was 66, 66 and 73 years with 65%, 70% and 66% women in G1 ( n = 353), G2 ( n = 388) and G3 ( n = 298) respectively. At baseline, there was no difference on CCI (CCI≈2) between treatment groups. However, comorbidity distribution differed prominently in asthma (22.1%, 26.3% and 11.4%), arrhythmia (19.3%, 19.3% and 27.2%), cystic fibrosis (0.8%, 4.6% and 0%), immune disorder (7.6%, 9% and 2.7%), pneumonia (49.0%, 41.8% and 32.6%), and tuberculosis (9.3%, 8.2% and 5.4%), and in immunosuppressant use (51%, 51.5% and 25.2%). Baseline hospitalization was 31.7% in G1, 33.0% in G2, and 25.8% in G3. At year 2, CCI stayed almost unchanged from the baseline scores (1.9 in G1, 2.0 in G2, and 1.9 in G3). Unadjusted hospitalization rates were 19.6%, 27.8% vs 20.8%, and adjusted rates were 44.5%, 56.1% and 47.8% in 3 groups respectively (Figure). G2 had a 60% increase in risk of hospitalization after adjustment (odds ratio (OR)=1.60, 95% CI: 1.11–2.29, P = 0.01) compared with G1 but no statistically significant difference compared with G3 (OR=1.40, P = 0.08). Cerebrovascular disease (OR=1.8, P < 0.02), COPD (OR=1.60, P < 0.01), cystic fibrosis (OR=5.85, P < 0.01), depression (OR=1.64, P < 0.05), and other lung disease (OR=1.42, P < 0.05) were associated with a higher risk of hospitalization at year 2 after NTMLD diagnosis. Conclusion: We observed a lower hospitalization rate in NTMLD patients receiving antibiotics that were concordant with first line ATS/IDSA guidelines recommendations in comparison with those who used other antibiotic regimens. Disclosures: E. Chou, Insmed Incorporated: Employee, Salary; G. Eagle, Insmed Incorporated: Employee, Salary; R. Zhang, Insmed Incorporated: Consultant, Consulting fee; P. Wang, Insmed Incorporated: Employee, Salary; Q. Zhang, Insmed Incorporated: Employee, Salary